Santa Barbara, Calif.-based Sientra Inc. (NASDAQ: SIEN) scored a big win this week, with the company reporting after the market closed Wednesday that the FDA had approved a final process enhancement for a manufacturing facility. As a result, Sientra is poising to regain market share with its Opus-branded breast implant products and ending an ordeal spawned by an inspection of a contract manufacturer in Brazil. Sientra closed at $11.98 Thursday after closing at $11.05 the previous day. Read More
Medicare coverage of telehealth, which is critical for many patients with implanted cardiac electrophysiology devices, has been slow in coming, but a new report on Medicare payments for telehealth recommends that the CMS review paid claims to claw back some instances of overpayment, which would constitute yet another example of the pay-and-chase paradigm that has drawn criticism in the past. Read More
